How To Select The Right Polymers For Your Modified Release Multiparticulate Capsule

By Richard Sidwell, Ph.D., Vice President and Chief Scientific Officer, Societal CDMO

Pharma companies aiming to tech transfer or scale-up modified release formulations and take into clinical studies often encounter hurdles when the formulation is not robust. The process is challenging to run, and dissolution performance varies from batch to batch or even capsule to capsule.

When selecting the right polymers for your modified release dosage form, the best starting point is to decide on the pharmacokinetic profile and then make the strategic formulation decisions about the dosage form (monolithic tablet or multiparticulate capsule) and the release profile (e.g., sustained, delayed, pulsatile) you desire. Review how to select the right polymers (and other best practices) and ensure you have a robust multiparticulate capsule formulation strategy.